Medicare AdvantageCoverageMedium impact
MA08.167, Pozelimab-bbfg (Veopoz®)
Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy
Effective date
May 27, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.167 for Pozelimab-bbfg (Veopoz®) has been updated and reissued. This is a pharmacy policy change that will take effect May 27, 2026, affecting coverage or requirements for this specific medication.
Action Required
By May 27, 2026: Review updated policy MA08.167 for Pozelimab-bbfg (Veopoz®) at the provided URL to understand specific coverage changes. Billing team must update procedures for this medication based on new policy requirements. Ensure providers are aware of any new documentation or prior authorization requirements.